MSI2 and acute myeloid leukemia: To examine if the MSI2:β-catenin interaction could be detected in patient cells, we performed an MSI2 Co-IP from a primary AML sample containing abundant levels of both proteins and where ample cellular material existed (AML patient #10) and confirmed MSI2 interaction with β-catenin, but not with GAPDH ruling out non-specific binding (Fig. 5E).